65
of those infants have below average neurodevelopment [8] . Currently, it is unknown if 66 ZIKV infection in humans confers lifelong immunity, however it is suggested that waning 67 immunity over time leads to more severe ZIKV in the future [9, 10] . It is thought that a 68 single infection or vaccination that generates neutralizing antibody (nAb) titers above 69 1:10 PRNT 50 (50% plaque reduction neutralization test) is enough to confer lifelong 70 immunity in other flaviviruses, such as yellow fever virus (YFV) or dengue virus (DENV) 71 [11, 12] . Antibodies to YFV 159 post rechallenge, and on days 10, 14, and 28 days post rechallenge (Fig 1) . On all days 160 throughout the study, plasma vRNA loads remained negative, indicating protection from 161 plasma viremia after ZIKV rechallenge.
162
163 181 Serum nAb responses were measured using a flow cytometry-based ZIKV 182 neutralization assay. Prior to rechallenge, all animals had high EC50 (50% effective 183 concentration) values (Fig 2A) , that were greater than the 1:10 PRNT50 values 12 228 initial ZIKV infection provides apparently protective immunity at least 27 months after 229 initial ZIKV infection. Primary ZIKV infection generated nAb titers above the 1:10 230 threshold deemed protective against re-infection for other flaviviruses (Fig 2) 249 Two animals used in our rechallenge study, C3 and C5, were previously part of a 13 251 study concluded that similar to human pregnancy, maternal-fetal transmission is highly 252 efficient with variable vRNA levels detected in all fetuses assessed. Despite a small 253 sample size in our rechallenge study (n = 2 animals initially infected during pregnancy), 254 we show that these animals develop immune responses similar to non-pregnant 255 animals. Following primary ZIKV infection during pregnancy in 2016, animal C5 has 256 gone on to give birth to two apparently healthy infants (in 2017 and 2018) and C3 has 257 gone on to give birth to one healthy infant (2019). While this study did not look at the 258 impacts of a ZIKV rechallenge during a second pregnancy, we show that subsequent 259 infants born to mothers who were previously infected with ZIKV are in qualitatively good 260 health. Future studies will need to determine if immunity elicited by a primary infection is 261 sufficient to protect a subsequent pregnancy from the effects of a ZIKV rechallenge 262 during pregnancy. Additionally, it will be important to characterize the extent of ZIKV-263 specific antibody responses in infants exposed to ZIKV in utero.
264 In summary, our study establishes a new experimentally defined minimal length of 265 protective immunity against ZIKV of up to 27 months. Future longitudinal studies will 266 need to assess ZIKV immunity of previously infected individuals at longer time frames 267 than we have in order to continue to define the maximum length of immunity elicited by 268 natural ZIKV infection. Establishing the true maximum length of ZIKV protective 269 immunity will be critical for understanding outbreak dynamics, the future transmission 270 potential of ZIKV, and influence future vaccination strategies. 
